The Board of Directors of Spago Nanomedical AB (publ) publishes a prospectus in connection with the rights issue of shares (the “Rights Issue”) which was approved by the Extraordinary General Meeting on January 15, 2021. The prospectus has today been approved and registered by the Swedish Supervisory Authority. The fully secured Rights Issue is expected to bring in approximately SEK 59.1 million before issue costs and, in the event of oversubscription, an additional up to approximately SEK 10 million before issue costs in a possible over-allotment issue.
The Board of Directors of Spago Nanomedical AB (publ) publishes a prospectus in connection with the rights issue of shares (the "Rights Issue") approved by the Extraordinary General Meeting on January 15, 2021. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority. The fully secured Rights Issue is expected to raise approximately SEK 59.1 million before issuecosts and, in the event of oversubscription, an additional up to approximately SEK 10 million before issue costs in a possible over-allotment issue.
Spago Nanomedical carries out the Rights Issue to forcefully drive the development of the company's radionuclide therapy, Tumorad®, forward. The proceeds from the issue are intended to be used to finance the final steps required to initiate phase I/II clinical studies with Tumorad®.
"With promising clinical results for SpagoPix validating our platformtechnology and the capital injection from the Rights Issue, we are in aposition to accelerate Tumorad® to clinical studies in cancer patients,"says CEO Mats Hansen.
The Rights Issue comprises a maximum of 7,886,129 shares. Anyone who on the record date February 5, 2021 was a shareholder in Spago Nanomedical has preferential rights to subscribe for shares in the Rights Issue. Each shareholder receives one (1) subscription right for each share held on the record date. Four (4) subscription rights entitle the holder to subscribe for one (1) share in the Company. The subscription price is SEK 7.50 per share. The public also has the opportunity to register an interest.
The prospectus, containing full terms and instructions, is available on the respective websites of the Company, the Issuing Institute and Naventus Corporate Finance AB (www.spagonanomedical.se, www.hagberganeborn.se, www.naventus.com). It will also be available on the Swedish Supervisory Authority's website www.fi.se. Registration forms will be available on the company's and Naventus Corporate Finance AB's respective websites. Furthermore, the registration form can be obtained by contacting the issuing institute Hagberg & Aneborn Fondkommission AB on +46 8 408 933 50.
Naventus Corporate Finance AB is a financial advisor and Cederquist KB is legal advisor in connection with the Rights Issue. Hagberg & Aneborn is an issuer in connection with the Rights Issue.
For further information, please contact: Mats Hansen, CEO Spago NanomedicalAB, +46 46 811 88, email@example.com, or Hanna Olsson, CFO Spago Nanomedical, +46 763 148 063, firstname.lastname@example.org.
Spago Nanomedical AB is a Swedish nanomedicine company in clinical development phase.The company's development project is based on a patented platform of polymeric materials with unique properties that can enable more accurate diagnosis and treatment of solid tumors. Spago Nanomedical's share is listed on Spotlight Stock Market in Stockholm (short name: SPAG). For more information, see www.spagonanomedical.se.